A Study to Evaluate Investigational Agents With or Without Pembrolizumab (MK-3475) in Participants With Advanced Esophageal Cancer Previously Exposed to Programmed Cell Death 1 Protein (PD-1)/ Programmed Cell Death Ligand 1 (PD-L1) Treatment (MK-3475-06B)
Esophageal Squamous Cell Carcinoma
No strong warning signs right now. The score counts warning signs; it is not a prediction.
Why this score
- +1.9
5 insiders sold shares within a month
Since Aug 13, 2026 · was worth 5, fading over time
Score over time
- Stage
- Phase 1/2
- Patients
- 230 (planned)
- Started
- May 16, 2023
- Main results expected
- Jun 11, 2027
- Fully finished
- Apr 10, 2029
- Results posted
- not yet
What counts as success
The trial's main goal(s), called the “primary outcome.”
Number of Participants Experiencing Dose-Limiting Toxicities (DLTs) During Safety Lead-in Phase
Measured over: Up to approximately 3 weeks
Number of Participants Who Experienced an Adverse Event (AE) During Safety Lead-in Phase
Measured over: Up to approximately 3 weeks
Number of Participants Who Discontinue Study Treatment Due to an AE During Safety Lead-in Phase
Measured over: Up to approximately 3 weeks
Objective Response Rate (ORR)
Measured over: Up to approximately 48 months
Changes Tremor has spotted
Show details (technical version)
Score inputs
- insider_selling_cluster: base 5, now 1.9, since 2026-08-13, fades (half-life)
Raw record changes
- none yet
Trial ID NCT05319730 · record last updated 2026-10-07 · checked 2026-11-09 15:47 UTC